GlassScriptPhysician profile
Lesley N Glover
NPI 1730140211
$6,858.75
in general payments reported to CMS, 2019-2025
41 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $1,558 · 2021: $991 · 2022: $721 · 2023: $860 · 2024: $753 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.41 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,036.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $962.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $726.14 | 2019-2025 | |
| Abbvie INC. | $721.51 | 2019-2025 | |
| Lilly USA, LLC | $438.67 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.98 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $232.50 | 2020-2023 | Gattex |
| Merck Sharp & Dohme LLC | $203.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $189.96 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $162.42 | 2022 | |
| Amgen INC. | $133.86 | 2020-2022 | |
| Antares Pharma, INC. | $118.80 | 2019-2021 | |
| Abbott Laboratories | $117.20 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $114.57 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $114.39 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.